{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:04:43Z","timestamp":1769105083564,"version":"3.49.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11899-025-00759-w","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:31:34Z","timestamp":1759494694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Epigenetic Mutations in Chronic Myelomonocytic Leukemia"],"prefix":"10.1007","volume":"20","author":[{"given":"Jenna","family":"Fernandez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Pradeep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"issue":"6","key":"759_CR1","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.27271","volume":"99","author":"MM Patnaik","year":"2024","unstructured":"Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. Am J Hematol. 2024;99(6):1142\u201365. https:\/\/doi.org\/10.1002\/ajh.27271.","journal-title":"Am J Hematol"},{"issue":"20","key":"759_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544.","journal-title":"Blood"},{"issue":"11","key":"759_CR3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u201328. https:\/\/doi.org\/10.1182\/blood.2022015850.","journal-title":"Blood"},{"issue":"7","key":"759_CR4","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1080\/10428194.2016.1258700","volume":"58","author":"GS Guru Murthy","year":"2017","unstructured":"Guru Murthy GS, Dhakal I, Mehta P. Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States. Leuk Lymphoma. 2017;58(7):1648\u201354. https:\/\/doi.org\/10.1080\/10428194.2016.1258700.","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"759_CR5","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1016\/j.ejca.2012.05.024","volume":"48","author":"O Visser","year":"2012","unstructured":"Visser O, Trama A, Maynadie M, Stiller C, Marcos-Gragera R, De Angelis R, et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer. 2012;48(17):3257\u201366. https:\/\/doi.org\/10.1016\/j.ejca.2012.05.024.","journal-title":"Eur J Cancer"},{"issue":"1","key":"759_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","volume":"112","author":"DE Rollison","year":"2008","unstructured":"Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45\u201352. https:\/\/doi.org\/10.1182\/blood-2008-01-134858.","journal-title":"Blood"},{"issue":"1","key":"759_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/ajh.25684","volume":"95","author":"MM Patnaik","year":"2020","unstructured":"Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95(1):97\u2013115. https:\/\/doi.org\/10.1002\/ajh.25684.","journal-title":"Am J Hematol"},{"issue":"7","key":"759_CR8","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1080\/1042819042000207271","volume":"45","author":"U Germing","year":"2004","unstructured":"Germing U, Kundgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma. 2004;45(7):1311\u20138. https:\/\/doi.org\/10.1080\/1042819042000207271.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"759_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3324\/haematol.2010.030957","volume":"96","author":"E Such","year":"2011","unstructured":"Such E, Cervera J, Costa D, Sole F, Vallespi T, Luno E, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96(3):375\u201383. https:\/\/doi.org\/10.3324\/haematol.2010.030957.","journal-title":"Haematologica"},{"issue":"12","key":"759_CR10","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/ajh.23846","volume":"89","author":"EA Wassie","year":"2014","unstructured":"Wassie EA, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French consortium study. Am J Hematol. 2014;89(12):1111\u20135. https:\/\/doi.org\/10.1002\/ajh.23846.","journal-title":"Am J Hematol"},{"issue":"8","key":"759_CR11","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/ajh.23751","volume":"89","author":"G Tang","year":"2014","unstructured":"Tang G, Zhang L, Fu B, Hu J, Lu X, Hu S, et al. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. Am J Hematol. 2014;89(8):813\u20138. https:\/\/doi.org\/10.1002\/ajh.23751.","journal-title":"Am J Hematol"},{"key":"759_CR12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027170","author":"A Tefferi","year":"2025","unstructured":"Tefferi A, Fathima S, Abdelmagid M, Alsugair A, Aperna F, Rezasoltani M, et al. BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia. Blood. 2025. https:\/\/doi.org\/10.1182\/blood.2024027170.","journal-title":"Blood"},{"issue":"1","key":"759_CR13","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1038\/bcj.2015.113","volume":"6","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Lasho TL, Vijayvargiya P, Finke CM, Hanson CA, Ketterling RP, et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6(1):e385. https:\/\/doi.org\/10.1038\/bcj.2015.113.","journal-title":"Blood Cancer J"},{"issue":"1","key":"759_CR14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3324\/haematol.2021.280203","volume":"108","author":"M Mei","year":"2023","unstructured":"Mei M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, et al. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica. 2023;108(1):150\u201360. https:\/\/doi.org\/10.3324\/haematol.2021.280203.","journal-title":"Haematologica"},{"issue":"19","key":"759_CR15","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"R Itzykson","year":"2013","unstructured":"Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428\u201336. https:\/\/doi.org\/10.1200\/JCO.2012.47.3314.","journal-title":"J Clin Oncol"},{"issue":"11","key":"759_CR16","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/leu.2014.125","volume":"28","author":"MM Patnaik","year":"2014","unstructured":"Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014;28(11):2206\u201312. https:\/\/doi.org\/10.1038\/leu.2014.125.","journal-title":"Leukemia"},{"issue":"22","key":"759_CR17","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616\u201327. https:\/\/doi.org\/10.1182\/blood-2013-08-518886.","journal-title":"Blood"},{"issue":"6","key":"759_CR18","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","volume":"145","author":"V Gelsi-Boyer","year":"2009","unstructured":"Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145(6):788\u2013800. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07697.x.","journal-title":"Br J Haematol"},{"issue":"12","key":"759_CR19","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.3324\/haematol.2009.011205","volume":"94","author":"O Kosmider","year":"2009","unstructured":"Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94(12):1676\u201381. https:\/\/doi.org\/10.3324\/haematol.2009.011205.","journal-title":"Haematologica"},{"issue":"2","key":"759_CR20","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1038\/bcj.2016.5","volume":"6","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Tefferi A. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6(2):e393. https:\/\/doi.org\/10.1038\/bcj.2016.5.","journal-title":"Blood Cancer J"},{"issue":"14","key":"759_CR21","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","volume":"118","author":"AM Jankowska","year":"2011","unstructured":"Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 2011;118(14):3932\u201341. https:\/\/doi.org\/10.1182\/blood-2010-10-311019.","journal-title":"Blood"},{"issue":"26","key":"759_CR22","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488\u201398. https:\/\/doi.org\/10.1056\/NEJMoa1408617.","journal-title":"N Engl J Med"},{"issue":"1","key":"759_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","volume":"126","author":"DP Steensma","year":"2015","unstructured":"Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9\u201316. https:\/\/doi.org\/10.1182\/blood-2015-03-631747.","journal-title":"Blood"},{"issue":"18","key":"759_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3238\/arztebl.2016.0317","volume":"113","author":"M Heuser","year":"2016","unstructured":"Heuser M, Thol F, Ganser A. Clonal hematopoiesis of indeterminate potential. Dtsch Arztebl Int. 2016;113(18):317\u201322. https:\/\/doi.org\/10.3238\/arztebl.2016.0317.","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"759_CR25","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/leu.2015.337","volume":"30","author":"CC Mason","year":"2016","unstructured":"Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, et al. Age-related mutations and chronic myelomonocytic leukemia. Leukemia. 2016;30(4):906\u201313. https:\/\/doi.org\/10.1038\/leu.2015.337.","journal-title":"Leukemia"},{"issue":"1","key":"759_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3324\/haematol.2024.286061","volume":"110","author":"L Marando","year":"2025","unstructured":"Marando L, Csizmar CM, Patnaik MM. Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovations. Haematologica. 2025;110(1):22\u201336. https:\/\/doi.org\/10.3324\/haematol.2024.286061.","journal-title":"Haematologica"},{"issue":"3","key":"759_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1182\/blood-2018-01-829937","volume":"132","author":"M Buscarlet","year":"2018","unstructured":"Buscarlet M, Provost S, Zada YF, Bourgoin V, Mollica L, Dube MP, et al. Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A. Blood. 2018;132(3):277\u201380. https:\/\/doi.org\/10.1182\/blood-2018-01-829937.","journal-title":"Blood"},{"issue":"12","key":"759_CR28","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","volume":"121","author":"R Itzykson","year":"2013","unstructured":"Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood. 2013;121(12):2186\u201398. https:\/\/doi.org\/10.1182\/blood-2012-06-440347.","journal-title":"Blood"},{"issue":"6","key":"759_CR29","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/s41375-023-01887-z","volume":"37","author":"T Lasho","year":"2023","unstructured":"Lasho T, Finke C, Timm M, Tefferi A, Mangaonkar A, Olteanu H, et al. Single cell proteogenomic analysis of aberrant monocytosis in TET2 mutant premalignant and malignant hematopoiesis. Leukemia. 2023;37(6):1384\u20137. https:\/\/doi.org\/10.1038\/s41375-023-01887-z.","journal-title":"Leukemia"},{"issue":"3","key":"759_CR30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrg3354","volume":"14","author":"ZD Smith","year":"2013","unstructured":"Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet. 2013;14(3):204\u201320. https:\/\/doi.org\/10.1038\/nrg3354.","journal-title":"Nat Rev Genet"},{"key":"759_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.gde.2013.11.015","volume":"25","author":"T Baubec","year":"2014","unstructured":"Baubec T, Schubeler D. Genomic patterns and context specific interpretation of DNA methylation. Curr Opin Genet Dev. 2014;25:85\u201392. https:\/\/doi.org\/10.1016\/j.gde.2013.11.015.","journal-title":"Curr Opin Genet Dev"},{"issue":"46","key":"759_CR32","doi-asserted-by":"publisher","first-page":"48350","DOI":"10.1074\/jbc.M403427200","volume":"279","author":"A Hermann","year":"2004","unstructured":"Hermann A, Goyal R, Jeltsch A. The Dnmt1 DNA-(cytosine-C5)-methyltransferase methylates DNA processively with high preference for hemimethylated target sites. J Biol Chem. 2004;279(46):48350\u20139. https:\/\/doi.org\/10.1074\/jbc.M403427200.","journal-title":"J Biol Chem"},{"issue":"3","key":"759_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/s0092-8674(00)81656-6","volume":"99","author":"M Okano","year":"1999","unstructured":"Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99(3):247\u201357. https:\/\/doi.org\/10.1016\/s0092-8674(00)81656-6.","journal-title":"Cell"},{"issue":"7310","key":"759_CR34","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/nature09303","volume":"466","author":"S Ito","year":"2010","unstructured":"Ito S, D\u2019Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 2010;466(7310):1129\u201333. https:\/\/doi.org\/10.1038\/nature09303.","journal-title":"Nature"},{"issue":"5929","key":"759_CR35","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1126\/science.1170116","volume":"324","author":"M Tahiliani","year":"2009","unstructured":"Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929):930\u20135. https:\/\/doi.org\/10.1126\/science.1170116.","journal-title":"Science"},{"issue":"3","key":"759_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/nrc3895","volume":"15","author":"L Yang","year":"2015","unstructured":"Yang L, Rau R, Goodell MA. DNMT3A in haematological malignancies. Nat Rev Cancer. 2015;15(3):152\u201365. https:\/\/doi.org\/10.1038\/nrc3895.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"759_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/ajh.24581","volume":"92","author":"MM Patnaik","year":"2017","unstructured":"Patnaik MM, Barraco D, Lasho TL, Finke CM, Hanson CA, Ketterling RP, et al. DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. Am J Hematol. 2017;92(1):56\u201361. https:\/\/doi.org\/10.1002\/ajh.24581.","journal-title":"Am J Hematol"},{"issue":"6047","key":"759_CR38","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1126\/science.1210597","volume":"333","author":"S Ito","year":"2011","unstructured":"Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011;333(6047):1300\u20133. https:\/\/doi.org\/10.1126\/science.1210597.","journal-title":"Science"},{"issue":"6047","key":"759_CR39","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1126\/science.1210944","volume":"333","author":"YF He","year":"2011","unstructured":"He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. 2011;333(6047):1303\u20137. https:\/\/doi.org\/10.1126\/science.1210944.","journal-title":"Science"},{"issue":"6","key":"759_CR40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrm3589","volume":"14","author":"WA Pastor","year":"2013","unstructured":"Pastor WA, Aravind L, Rao A. Tectonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol. 2013;14(6):341\u201356. https:\/\/doi.org\/10.1038\/nrm3589.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"23","key":"759_CR41","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1101\/gad.179184.111","volume":"25","author":"H Wu","year":"2011","unstructured":"Wu H, Zhang Y. Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev. 2011;25(23):2436\u201352. https:\/\/doi.org\/10.1101\/gad.179184.111.","journal-title":"Genes Dev"},{"issue":"11","key":"759_CR42","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.4161\/cc.8.11.8580","volume":"8","author":"LM Iyer","year":"2009","unstructured":"Iyer LM, Tahiliani M, Rao A, Aravind L. Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle. 2009;8(11):1698\u2013710. https:\/\/doi.org\/10.4161\/cc.8.11.8580.","journal-title":"Cell Cycle"},{"issue":"7447","key":"759_CR43","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nature12052","volume":"497","author":"M Ko","year":"2013","unstructured":"Ko M, An J, Bandukwala HS, Chavez L, Aijo T, Pastor WA, et al. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature. 2013;497(7447):122\u20136. https:\/\/doi.org\/10.1038\/nature12052.","journal-title":"Nature"},{"key":"759_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00210","volume":"9","author":"Y Feng","year":"2019","unstructured":"Feng Y, Li X, Cassady K, Zou Z, Zhang X. TET2 function in hematopoietic malignancies, immune regulation, and DNA repair. Front Oncol. 2019;9:210. https:\/\/doi.org\/10.3389\/fonc.2019.00210.","journal-title":"Front Oncol"},{"issue":"22","key":"759_CR45","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","volume":"360","author":"F Delhommeau","year":"2009","unstructured":"Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289\u2013301. https:\/\/doi.org\/10.1056\/NEJMoa0810069.","journal-title":"N Engl J Med"},{"issue":"9","key":"759_CR46","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1038\/bcj.2016.82","volume":"6","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Zahid MF, Lasho TL, Finke C, Ketterling RL, Gangat N, et al. Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. Blood Cancer J. 2016;6(9):e472. https:\/\/doi.org\/10.1038\/bcj.2016.82.","journal-title":"Blood Cancer J"},{"issue":"5","key":"759_CR47","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41375-019-0690-7","volume":"34","author":"G Coltro","year":"2020","unstructured":"Coltro G, Mangaonkar AA, Lasho TL, Finke CM, Pophali P, Carr R, et al. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. Leukemia. 2020;34(5):1407\u201321. https:\/\/doi.org\/10.1038\/s41375-019-0690-7.","journal-title":"Leukemia"},{"issue":"3","key":"759_CR48","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1182\/bloodadvances.2018024216","volume":"3","author":"H Awada","year":"2019","unstructured":"Awada H, Nagata Y, Goyal A, Asad MF, Patel B, Hirsch CM, et al. Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia. Blood Adv. 2019;3(3):339\u201349. https:\/\/doi.org\/10.1182\/bloodadvances.2018024216.","journal-title":"Blood Adv"},{"issue":"12","key":"759_CR49","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1038\/s41375-022-01733-8","volume":"36","author":"N Garcia-Gisbert","year":"2022","unstructured":"Garcia-Gisbert N, Arenillas L, Roman-Bravo D, Rodriguez-Sevilla JJ, Fernandez-Rodriguez C, Garcia-Avila S, et al. Multi-hit TET2 mutations as a differential molecular signature of oligomonocytic and overt chronic myelomonocytic leukemia. Leukemia. 2022;36(12):2922\u20136. https:\/\/doi.org\/10.1038\/s41375-022-01733-8.","journal-title":"Leukemia"},{"key":"759_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107391","volume":"134","author":"M Gurney","year":"2023","unstructured":"Gurney M, Greipp PT, Gliem T, Knudson R, Al-Kali A, Gangat N, et al. TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia. Leuk Res. 2023;134:107391. https:\/\/doi.org\/10.1016\/j.leukres.2023.107391.","journal-title":"Leuk Res"},{"key":"759_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02648-w","author":"CM Csizmar","year":"2025","unstructured":"Csizmar CM, Natu A, Gurney M, Fathima S, Alsugair AKA, Kanagal-Shamanna R, et al. Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes. Leukemia. 2025. https:\/\/doi.org\/10.1038\/s41375-025-02648-w.","journal-title":"Leukemia"},{"issue":"2","key":"759_CR52","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1038\/bcj.2015.9FromNLMPubMed-not-MEDLINE","volume":"5","author":"MM Patnaik","year":"2015","unstructured":"Patnaik MM, Wassie EA, Padron E, Onida F, Itzykson R, Lasho TL, et al. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J. 2015;5(2):e280. https:\/\/doi.org\/10.1038\/bcj.2015.9FromNLMPubMed-not-MEDLINE.","journal-title":"Blood Cancer J"},{"issue":"2","key":"759_CR53","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/leu.2017.186","volume":"32","author":"V Santini","year":"2018","unstructured":"Santini V, Allione B, Zini G, Gioia D, Lunghi M, Poloni A, et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. 2018;32(2):413\u20138. https:\/\/doi.org\/10.1038\/leu.2017.186.","journal-title":"Leukemia"},{"issue":"7","key":"759_CR54","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/ajh.25488","volume":"94","author":"T Coston","year":"2019","unstructured":"Coston T, Pophali P, Vallapureddy R, Lasho TL, Finke CM, Ketterling RP, et al. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. Am J Hematol. 2019;94(7):767\u201379. https:\/\/doi.org\/10.1002\/ajh.25488.","journal-title":"Am J Hematol"},{"issue":"28","key":"759_CR55","doi-asserted-by":"publisher","first-page":"10396","DOI":"10.1021\/ja4028346","volume":"135","author":"R Yin","year":"2013","unstructured":"Yin R, Mao SQ, Zhao B, Chong Z, Yang Y, Zhao C, et al. Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J Am Chem Soc. 2013;135(28):10396\u2013403. https:\/\/doi.org\/10.1021\/ja4028346.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"759_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-020-01220-9","volume":"3","author":"Y Guan","year":"2020","unstructured":"Guan Y, Greenberg EF, Hasipek M, Chen S, Liu X, Kerr CM, et al. Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. Commun Biol. 2020;3(1):493. https:\/\/doi.org\/10.1038\/s42003-020-01220-9.","journal-title":"Commun Biol"},{"issue":"1","key":"759_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-022-01404-6","volume":"15","author":"A Taira","year":"2023","unstructured":"Taira A, Palin K, Kuosmanen A, Valimaki N, Kuittinen O, Kuismin O, et al. Vitamin C boosts DNA demethylation in TET2 germline mutation carriers. Clin Epigenetics. 2023;15(1):7. https:\/\/doi.org\/10.1186\/s13148-022-01404-6.","journal-title":"Clin Epigenetics"},{"issue":"4","key":"759_CR58","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1172\/JCI98747","volume":"129","author":"N Shenoy","year":"2019","unstructured":"Shenoy N, Bhagat TD, Cheville J, Lohse C, Bhattacharyya S, Tischer A, et al. Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma. J Clin Invest. 2019;129(4):1612\u201325. https:\/\/doi.org\/10.1172\/JCI98747.","journal-title":"J Clin Invest"},{"issue":"23","key":"759_CR59","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood.2024024962","volume":"144","author":"Z Xie","year":"2024","unstructured":"Xie Z, Fernandez J, Lasho T, Finke C, Amundson M, McCullough KB, et al. High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations. Blood. 2024;144(23):2456\u201361. https:\/\/doi.org\/10.1182\/blood.2024024962.","journal-title":"Blood"},{"issue":"2","key":"759_CR60","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0173","volume":"2","author":"Y Guan","year":"2021","unstructured":"Guan Y, Tiwari AD, Phillips JG, Hasipek M, Grabowski DR, Pagliuca S, et al. A therapeutic strategy for preferential targeting of TET2 mutant and TET-dioxygenase deficient cells in myeloid neoplasms. Blood Cancer Discov. 2021;2(2):146\u201361. https:\/\/doi.org\/10.1158\/2643-3230.BCD-20-0173.","journal-title":"Blood Cancer Discov"},{"issue":"8","key":"759_CR61","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1158\/1078-0432.CCR-13-1333","volume":"22","author":"O Clark","year":"2016","unstructured":"Clark O, Yen K, Mellinghoff IK. Molecular pathways: isocitrate dehydrogenase mutations in cancer. Clin Cancer Res. 2016;22(8):1837\u201342. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1333.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"759_CR62","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ccr.2013.03.005","volume":"23","author":"D Ye","year":"2013","unstructured":"Ye D, Ma S, Xiong Y, Guan KL. R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. Cancer Cell. 2013;23(3):274\u20136. https:\/\/doi.org\/10.1016\/j.ccr.2013.03.005.","journal-title":"Cancer Cell"},{"issue":"1","key":"759_CR63","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/leu.2011.298","volume":"26","author":"MM Patnaik","year":"2012","unstructured":"Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, Knudson RA, et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia. 2012;26(1):101\u20135. https:\/\/doi.org\/10.1038\/leu.2011.298.","journal-title":"Leukemia"},{"issue":"6","key":"759_CR64","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41375-022-01551-y","volume":"36","author":"C Walsh","year":"2022","unstructured":"Walsh C, Hunter A, Lasho T, Finke C, Ketterling R, Komrokji R, et al. Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia. Leukemia. 2022;36(6):1693\u20136. https:\/\/doi.org\/10.1038\/s41375-022-01551-y.","journal-title":"Leukemia"},{"key":"759_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14123012","author":"M Messina","year":"2022","unstructured":"Messina M, Piciocchi A, Ottone T, Paolini S, Papayannidis C, Lessi F, et al. Prevalence and prognostic role of IDH mutations in acute myeloid leukemia: results of the GIMEMA AML1516 protocol. Cancers. 2022. https:\/\/doi.org\/10.3390\/cancers14123012.","journal-title":"Cancers"},{"issue":"11","key":"759_CR66","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1038\/leu.2015.91","volume":"29","author":"RJ Molenaar","year":"2015","unstructured":"Molenaar RJ, Thota S, Nagata Y, Patel B, Clemente M, Przychodzen B, et al. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia. 2015;29(11):2134\u201342. https:\/\/doi.org\/10.1038\/leu.2015.91.","journal-title":"Leukemia"},{"issue":"1","key":"759_CR67","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13148-023-01529-2","volume":"15","author":"X Chen","year":"2023","unstructured":"Chen X, Xing H, Xie X, Kou L, Li J, Li Y. Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis. Clin Epigenetics. 2023;15(1):113. https:\/\/doi.org\/10.1186\/s13148-023-01529-2.","journal-title":"Clin Epigenetics"},{"issue":"6132","key":"759_CR68","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1126\/science.1234769","volume":"340","author":"F Wang","year":"2013","unstructured":"Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013;340(6132):622\u20136. https:\/\/doi.org\/10.1126\/science.1234769.","journal-title":"Science"},{"issue":"2","key":"759_CR69","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","volume":"22","author":"O Abdel-Wahab","year":"2012","unstructured":"Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 2012;22(2):180\u201393. https:\/\/doi.org\/10.1016\/j.ccr.2012.06.032.","journal-title":"Cancer Cell"},{"key":"759_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8307","volume":"6","author":"A Balasubramani","year":"2015","unstructured":"Balasubramani A, Larjo A, Bassein JA, Chang X, Hastie RB, Togher SM, et al. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex. Nat Commun. 2015;6:7307. https:\/\/doi.org\/10.1038\/ncomms8307.","journal-title":"Nat Commun"},{"issue":"7295","key":"759_CR71","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nature08966","volume":"465","author":"JC Scheuermann","year":"2010","unstructured":"Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature. 2010;465(7295):243\u20137. https:\/\/doi.org\/10.1038\/nature08966.","journal-title":"Nature"},{"issue":"7","key":"759_CR72","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/leu.2013.88","volume":"27","author":"MM Patnaik","year":"2013","unstructured":"Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27(7):1504\u201310. https:\/\/doi.org\/10.1038\/leu.2013.88.","journal-title":"Leukemia"},{"issue":"1","key":"759_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29142-6","volume":"13","author":"M Binder","year":"2022","unstructured":"Binder M, Carr RM, Lasho TL, Finke CM, Mangaonkar AA, Pin CL, et al. Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia. Nat Commun. 2022;13(1):1434. https:\/\/doi.org\/10.1038\/s41467-022-29142-6.","journal-title":"Nat Commun"},{"issue":"10","key":"759_CR74","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena C, Galli A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408\u201317. https:\/\/doi.org\/10.1182\/blood-2016-05-714030.","journal-title":"Blood"},{"issue":"13","key":"759_CR75","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1007\/s00018-019-03084-7","volume":"76","author":"S Asada","year":"2019","unstructured":"Asada S, Fujino T, Goyama S, Kitamura T. The role of ASXL1 in hematopoiesis and myeloid malignancies. Cell Mol Life Sci. 2019;76(13):2511\u201323. https:\/\/doi.org\/10.1007\/s00018-019-03084-7.","journal-title":"Cell Mol Life Sci"},{"issue":"8","key":"759_CR76","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000610","volume":"5","author":"N van Gils","year":"2021","unstructured":"van Gils N, Martianez Canales T, Vermue E, Rutten A, Denkers F, van der Deure T, et al. The novel oral BET-CBP\/p300 dual inhibitor NEO2734 is highly effective in eradicating acute myeloid leukemia blasts and stem\/progenitor cells. Hemasphere. 2021;5(8):e610. https:\/\/doi.org\/10.1097\/HS9.0000000000000610.","journal-title":"Hemasphere"},{"key":"759_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216949","volume":"593","author":"M Yao","year":"2024","unstructured":"Yao M, Jiang X, Xiao F, Lv X, Sheng M, Xing W, et al. Targeting BIRC5 as a therapeutic approach to overcome ASXL1-associated decitabine resistance. Cancer Lett. 2024;593:216949. https:\/\/doi.org\/10.1016\/j.canlet.2024.216949.","journal-title":"Cancer Lett"},{"issue":"1","key":"759_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79736-7","volume":"11","author":"L Xu","year":"2021","unstructured":"Xu L, Yu W, Xiao H, Lin K. BIRC5 is a prognostic biomarker associated with tumor immune cell infiltration. Sci Rep. 2021;11(1):390. https:\/\/doi.org\/10.1038\/s41598-020-79736-7.","journal-title":"Sci Rep"},{"issue":"1","key":"759_CR79","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2017-02-739490","volume":"130","author":"A Iwama","year":"2017","unstructured":"Iwama A. Polycomb repressive complexes in hematological malignancies. Blood. 2017;130(1):23\u20139. https:\/\/doi.org\/10.1182\/blood-2017-02-739490.","journal-title":"Blood"},{"issue":"2","key":"759_CR80","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/ng.518","volume":"42","author":"RD Morin","year":"2010","unstructured":"Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2):181\u20135. https:\/\/doi.org\/10.1038\/ng.518.","journal-title":"Nat Genet"},{"issue":"17","key":"759_CR81","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.2217\/fon-2020-1244","volume":"17","author":"E Julia","year":"2021","unstructured":"Julia E, Salles G. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed\/refractory follicular lymphoma. Future Oncol. 2021;17(17):2127\u201340. https:\/\/doi.org\/10.2217\/fon-2020-1244.","journal-title":"Future Oncol"},{"issue":"4","key":"759_CR82","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","volume":"13","author":"SK Knutson","year":"2014","unstructured":"Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. 2014;13(4):842\u201354. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0773.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"759_CR83","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ng.621","volume":"42","author":"T Ernst","year":"2010","unstructured":"Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42(8):722\u20136. https:\/\/doi.org\/10.1038\/ng.621.","journal-title":"Nat Genet"},{"issue":"8","key":"759_CR84","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/ng.620FromNLMMedline","volume":"42","author":"G Nikoloski","year":"2010","unstructured":"Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010;42(8):665\u20137. https:\/\/doi.org\/10.1038\/ng.620FromNLMMedline.","journal-title":"Nat Genet"},{"issue":"1","key":"759_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0045-4","volume":"8","author":"MM Patnaik","year":"2018","unstructured":"Patnaik MM, Vallapureddy R, Lasho TL, Hoversten KP, Finke CM, Ketterling R, et al. EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. Blood Cancer J. 2018;8(1):12. https:\/\/doi.org\/10.1038\/s41408-017-0045-4.","journal-title":"Blood Cancer J"},{"issue":"3","key":"759_CR86","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s12185-014-1670-3","volume":"101","author":"K Zoi","year":"2015","unstructured":"Zoi K, Cross NC. Molecular pathogenesis of atypical CML, CMML and MDS\/MPN-unclassifiable. Int J Hematol. 2015;101(3):229\u201342. https:\/\/doi.org\/10.1007\/s12185-014-1670-3.","journal-title":"Int J Hematol"},{"issue":"5","key":"759_CR87","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2011-07-367243","volume":"119","author":"J Score","year":"2012","unstructured":"Score J, Hidalgo-Curtis C, Jones AV, Winkelmann N, Skinner A, Ward D, et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic\/myeloproliferative neoplasms. Blood. 2012;119(5):1208\u201313. https:\/\/doi.org\/10.1182\/blood-2011-07-367243.","journal-title":"Blood"},{"issue":"7163","key":"759_CR88","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nature06145","volume":"449","author":"K Agger","year":"2007","unstructured":"Agger K, Cloos PA, Christensen J, Pasini D, Rose S, Rappsilber J, et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature. 2007;449(7163):731\u20134. https:\/\/doi.org\/10.1038\/nature06145.","journal-title":"Nature"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00759-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-025-00759-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00759-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:20:05Z","timestamp":1769044805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-025-00759-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["759"],"URL":"https:\/\/doi.org\/10.1007\/s11899-025-00759-w","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"12"}}